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The Ras/RAF/MEK/ERK pathway is an essential signaling cascade
for various refractory cancers, such as those with mutant KRAS
(mKRAS) and BRAF (mBRAF). However, there are unsolved ambi-
guities underlying mechanisms for this growth signaling thereby
creating therapeutic complications. This study shows that a vital
component of the pathway CRAF is directly impacted by an end
product of the cascade, glutathione transferases (GST) P1 (GSTP1),
driving a previously unrecognized autocrine cycle that sustains
proliferation of mKRAS and mBRAF cancer cells, independent of
oncogenic stimuli. The CRAF interaction with GSTP1 occurs at its
N-terminal regulatory domain, CR1 motif, resulting in its stabiliza-
tion, enhanced dimerization, and augmented catalytic activity.
Consistent with the autocrine cycle scheme, silencing GSTP1
brought about significant suppression of proliferation of mKRAS
and mBRAF cells in vitro and suppressed tumorigenesis of the
xenografted mKRAS tumor in vivo. GSTP1 knockout mice showed
significantly impaired carcinogenesis of mKRAS colon cancer. Con-
sequently, hindering the autocrine loop by targeting CRAF/GSTP1
interactions should provide innovative therapeutic modalities for
these cancers.
mKRAS and mBRAF cancers | autocrine growth cycle | CRAF/GSTP1
complex | refractory cancers
The Ras/RAF/MEK/ERK mitogen-activated protein kinase(MAPK) signaling pathway transduces an essential signal for
cell growth and for apoptosis prevention. Thus, gain-of-function
mutations of the components in this pathway, such as mKRAS
and mBRAF, cause common human cancers including pancre-
atic, colon, lung cancers, and malignant melanomas. Efforts to
develop effective therapeutic small molecule inhibitors against
mKRAS cancers, however, have been largely unsuccessful due to
its undruggable nature (1–3).
Regarding mBRAF cancers which share the common RAF/
MEK/ERK cascade with mKRAS cancers, although certain
kinase-specific inhibitors have been developed, they are ham-
pered by vulnerability to drug resistance of which the underlying
mechanisms are variable (4, 5). Moreover, the use of some RAF
inhibitors causes paradoxical effects, such as unexpected growth
of mKRAS cells (6) and the occurrence of cutaneous toxicities
including squamous cell carcinomas and keratoachanthomas (7).
To overcome therapeutic hurdles of directly targeting oncogenic
factors, such as mKRAS and mBRAF, attempts have been made
to inhibit downstream signal components, such as MEK or ERK.
Although these yielded some promising outcomes in clinical
studies in both mKRAS and mBRAF cancers (8), ERK-dependent
feedback effects which, instead, caused growth enhancement were
often experienced (9).
A recently developed BRAF inhibitor with high specificity
PLX8394, which efficiently blocks activity of a downstream signal
component ERK, has been shown to evade innate and acquired
resistance as revealed by in vitro and in vivo studies (10). How-
ever, evaluation of clinical therapeutic outcomes or long-term
results remain elusive. More recently, combination strategies
linking inhibition of BRAF, ERK, and EGFR have demon-
strated some clinical benefits and have been shown to overcome
RAF inhibitor induced paradoxical activation of MAP kinases
(11, 12). In these trials as well, targeting signal components, in
particular, multiple components, despite promising antitumor
effects, contend with inevitable toxicities in normal tissues (13).
Thus, a theoretically desirable treatment strategy to overcome
the obstacles may involve manipulation of factor(s) distinct from
the signal components but that positively modulate the MAP
kinase cascade via bystander effects and are selectively expressed
or closely associated with the oncogenic features of these can-
cers. We posit that an autocrine signal loop formed by interac-
tions of GSTP1 with CRAF can be a paradigm for this strategy.
GSTP1 was clinically implicated for its use as a tumor marker
(14) and in detoxification of certain types of anticancer drugs
(15). Growth promoting activity of GSTP1 on cancer cells, based
on the finding that silencing GSTP1 or GSTP inhibitors
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suppressed their growth, have also been reported, although de-
tails of molecular mechanisms underlying the growth promoting
activity was not exploited (16). We have previously demonstrated
contemporaneous positivity of KRAS mutations and GSTP1
expression in specimens of human colon cancers, adenomas, and
aberrant crypt foci (ACF) and confirmed a close correlation
between levels of GSTP1 mRNA and mutation status of KRAS
in those tissues (17). We also showed that GSTP1 was induced by
v-Kras transfection in KRAS wild-type (WT) colon-cancer cells
(17). Based on these earlier observations, a previously unex-
pected pivotal role of GSTP1 in the growth of refractory cancers,
such as those with mKRAS and mBRAF which transduce RAF/
MEK/ERK signaling is unveiled here. In these cells, GSTP1 as
an end product of RAF/MEK/ERK signaling, interacts with
CRAF, forming an autocrine signal loop to impede its protea-
somal degradation and to enhance its dimer formation and
enzyme activity.
Accordingly, in this study, we propose an autocrine growth
signaling formed by CRAF/GSTP1 interactions in mKRAS and
mBRAF cancers and suggest an approach to overcome certain
types of therapeutic refractoriness, such as insufficient efficacy of
targeting oncogenic stimuli by hindering this autocrine signal,
namely, the CRAF/GSTP1 complex.
Results
Correlations between GSTP1 Expression and KRAS or BRAFMutations.
Relationships between KRAS mutations and expression of GST
isoenzymes were determined. Among the isoenzymes tested in
WT KRAS (WTKRAS) and mKRAS cells, only GSTP1 correlated
with KRAS mutations (SI Appendix, Fig. S1A). The study in a
wider variety of malignant cell lines which included those with
mKRAS or mBRAF and those without these mutations disclosed
that GSTP1 expression was well defined in cells with mutations,
whereas it was not detected in cells with WTKRAS/WTBRAF (SI
Appendix, Fig. S1B).
Immunohistochemical quantification of GSTP1 expression in
human colon-cancer specimens (SI Appendix, Fig. S1 C and D)
revealed compatible results with the cancer cell lines, showing
uniformly higher levels in mKRAS compared with those in
WTKRAS specimens. To elucidate a possible cause-and-effect
relationship between mKRAS and GSTP1 expression, the
mKRAS gene (KRAS12V) was transduced to WTKRAS HepG2
and MCF7 cells, and clear induction of GSTP1 was confirmed
(SI Appendix, Fig. S1E). Furthermore, based on our previous
premise that expression of GSTP1 is controlled by the AP-1
transcription factor (17), the c-FOS transcription factor which is
directly induced by RAF/MEK/ERK signaling (18) was silenced,
resulting in significant suppression of GSTP1 in mKRAS M7609
and A 549 cells (SI Appendix, Fig. S1F).
Suppression of Proliferation of mKRAS Cells by Small Interfering RNA
GSTP1. To determine whether GSTP1 somehow contributes to
the growth of mKRAS cancers, small interfering RNA (siRNA)
GSTP1 (siGSTP1) was initially employed. Three siRNAs with
different sequences were found to be comparable for their si-
lencing capacity of GSTP1 and growth suppressive effects on a
mKRAS cell line (SI Appendix, Fig. S2 A and B).
To further assure the target sequence specificity of siGSTP1,
we carried out an experiment in PANC-1 cells transfected with
siGSTP1-resistant complementary DNA (cDNA) which encodes
the same amino acids as those of the authentic GSTP1 protein
but has distinct codons from the natural GSTP1 gene with sub-
stitutions of four nucleotides in the siGSTP1 target sequence. To
distinguish between GSTP1 proteins expressed by transfected
cDNAs from endogenous GSTP1 proteins by Western blotting,
the cDNAs were tagged by FLAG so that GSTP1 proteins
expressed by the transfected cDNAs migrated at higher molec-
ular weights relative to the endogenous GSTP1 (SI Appendix,
Fig. S2C). As expected, no suppressive effects of siGSTP1 on the
GSTP1 protein expressed by siGSTP1-resistant cDNA were
observed while significant suppression of GSTP1 protein
expressed by authentic GSTP1 cDNA and endogenous GSTP1
by siGSTP1 was evident (SI Appendix, Fig. S2C). These results
verified the target specificity of siGSTP1 used in the present
study. Transfection of siGSTP1 to the mKRAS cells at three
different dosages (10, 25, and 50 nM) evoked clear dose-
dependent growth suppression (SI Appendix, Fig. S2D), and
this siGSTP1 exhibited significant growth suppressive effects on
all 10 mKRAS cell lines examined (Fig. 1A). The mechanisms of
growth suppression were then analyzed by dye exclusion assay for
cell viability (SI Appendix, Fig. S2E), by FACS for cell cycle (SI
Appendix, Fig. S2F), and by Western blotting for apoptosis (SI
Appendix, Fig. S2G).
These analyses indicated that siGSTP1 treatment evoked
transition of the S-phase cells into the G1 or sub-G1 phase and
20–40% of the cell population underwent cell death due to ap-
optosis (SI Appendix, Fig. S2F). Nonspecific inhibitory effects of
the siGSTP1 on cell growth were ruled out because it did not
cause any growth suppression wtKRAS cells (Fig. 1A). The
growth promoting activity of GSTP1 was further confirmed by
transfection of GSTP1 (AxCAhGSTP1) which resulted in sig-
nificant growth enhancement of WTKRAS Hep G2 cells
(Fig. 1B).
Effects of Short Hairpin RNA GSTP1 on Tumorigenesis of Xenografted
mKRAS Cells. To substantiate the above in vitro results, in vivo
effects of GSTP1 silencing on tumorigenesis were verified. Since
short hairpin RNA (shRNA) expressing mKRAS cells are un-
likely to survive under the continuous suppressive pressure of
GSTP1 silencing on growth, we employed an inducible shRNA
GSTP1 approach using a green fluorescence protein (GFP)-
doxycycline (Dox) system.
The mKRAS cells were transduced with lentiviral vector
designed to express shGSTP1 by triggering with Dox, and un-
derwent limiting dilution yielding bright GFP positive clones
upon Dox addition. Colony formation of cloned mKRAS cells
was markedly suppressed by addition of Dox to agar gel whereas
colonies of WTKRAS cells were not suppressed at all by Dox (SI
Appendix, Fig. S3A). Severe combined immunodeficient (SCID)
mice inoculated with these cells showed marked reduction of the
tumor growth (Fig. 1C and SI Appendix, Fig. S3B) and sup-
pression of GSTP1 expression (SI Appendix, Fig. S3C) upon
addition of Dox to their drinking water, whereas tumor growth of
WTKRAS cells were not affected by Dox addition at all (Fig. 1C
and SI Appendix, Fig. S3 B and C).
Impaired Colon Carcinogenesis Induced by Azoxymethane in Gstp1p2
Null Mice. To support the outcome of gene-silencing experiments
described above, a gene-deletion approach utilizing Gstp null
mice (Gstp1p2−/− mice) was employed. The mKRAS relevant
colon carcinogenesis was induced by administration of azoxy-
methane (AOM) to these mice and their littermates (Fig. 2A).
The incidence of KRAS mutations in the precancerous lesions,
ACF (19), and colon-cancer tissues of WT mice treated with
AOM were nearly 70% (Fig. 2B).
Gstp expression levels in ACF and colon cancer of littermate
mice treated with AOM were significantly elevated as compared
to those in their normal colon epithelium (Fig. 2 C, D, and E). By
contrast, the number of ACF and colon-cancer lesions in
Gstp1p2 −/− mice after AOM treatment was appreciably lower than
those in littermate mice (Fig. 2 F andG). These results confirmed a
pivotal role of GSTP1 in mKRAS colon carcinogenesis, consistent
with suppressed proliferation and tumorigenesis of mKRAS cells,
revealed by GSTP1 silencing.

































































































































































































































































































Fig. 1. Effects of GSTP1 silencing or forced expression on growth of mKRAS or WTKRAS cancer cells. (A) Growth curves of mKRAS cancer cells treated with
siGSTP1. Cell number of mKRAS cancer cells was counted for 5 d after siGSTP1 transfection. Data represent the mean ± SD of three independent experiments.
Open circles represent cells treated with siGSTP1 and closed squares, siRNA control (siControl). *P < 0.05 by Student t test. (B) Enhanced proliferation of
WTKRAS cancer cells by forced expression of GSTP1. HepG2 cells were infected with 10 multiplicity of infection (MOI) of AxCAhGSTP1 and AxCAwt, and cell
numbers were counted for 5 d after infection. Data represent the mean ± SD of three independent experiments. *P < 0.05 by Student t test. (C) Significant
suppression of tumorigenesis of mKRAS cancer cells but not that of WTKRAS cancer cells by GSTP1 silencing. Cells expressing Dox-inducible shGSTP1 were
inoculated subcutaneously into nonobese diabetic/SCID mice and subjected to Dox treatment (0.2 g/L). *P < 0.05 by Student t test.








































































































































































































(74%)ACF from AOM-treated mice
Fig. 2. Suppressive effects of Gstp1p2 gene deletion on the formation of ACF and colon cancers in AOM-treated mice. (A) Protocol for AOM treatment.
Gstp1p2 null (Gstp1p2[−/−]) and WT (Gstp1p2[+/+]) mice were injected with AOM (10 mg/kg intraperitoneally), and the number of ACF and cancer nodules
were counted at 8 and 16 wk, respectively. (B) Two-step PCR-restriction fragment length polymorphism (RFLP) for mKRAS in ACF and colon-cancer tissues of
Gstp null mice treated with AOM and normal colon epithelia of littermate mice. Portions of ACF and cancer in tissues were microlaser dissected and subjected
to PCR-RFLP. (C and D) Immunohistochemical staining for Gstp of ACF and colon-cancer tissues from AOM-treated mice and those of normal colon epithelia
from littermate mice. Staining intensity of Gstp in tissues (C) was quantified by grayscale image analysis (D). The dotted line indicated the cutoff level for
normal grayscale level as defined mean ± 2 SD (i.e., 0.13). (E) % Gstp mRNA change in ACF and colon-cancer tissues from AOM-treated mice and littermate
mice. Portions of ACF and cancer in tissues were microlaser dissected and subjected to mRNA analysis. Gstp mRNA levels were assessed by the method de-
scribed inMaterials and Methods. The dotted line indicated the cutoff level for the normal Gstp mRNA level as defined mean ± 2 SD (i.e., 4.2). (F and G) Effects
of Gstp1p2 knockout on the formation of ACF (F) and colon polyps (G) in AOM-treated mice. *P < 0.01; by Mann–Whitney u test.








































c-jun N-Terminal Kinase Is Irrelevant for GSTP1 Effects on mKRAS Cell
Growth. Since GSTP1 has long been proposed to affect cancer
cell growth by interaction with c-jun N-terminal kinase (JNK)
(20), effects of a JNK inhibitor SP600125 on growth of mKRAS
cells which were treated with siGSTP1 or siControl were deter-
mined. With 5–10 μM of SP600125 which caused substantial
inhibition of p-JNK (Thr183/Tyr185) (SI Appendix, Fig. S4A),
cell numbers and cell death were not affected at all, whereas only
when the cells were treated with both siGSTP1 and the inhibitor,
marked growth suppression was observed (SI Appendix, Fig. S4 B
and C). Furthermore, siRNA JNK did not affect the growth of
mKRAS cells (SI Appendix, Fig. S4D), indicating that growth
promotion of mKRAS cells by GSTP1 occurs independently from
activation of JNK.
Mechanism for Growth Promotion of mKRAS Cells by GSTP1 in
Relation to Their Signaling Pathway. The relevance of the growth
promoting activity of GSTP1 to the signaling cascade of the
mKRAS cells was considered. By treatment with siGSTP1, while
most MAPK relevant components including KRAS-GTP,
KRAS, phosphorylated BRAF, BRAF, ARAF, and COT1 were
unchanged (SI Appendix, Fig. S5 A–C), but only the CRAF
protein was appreciably reduced without reduction of mRNA
(Fig. 3A and SI Appendix, Fig. S5D) but with concomitant sup-
pression of phosphorylated CRAF, phosphorylated MEK, and
phosphorylated ERK (Fig. 3A), suggesting that GSTP1 targets
CRAF, leading to the activation of downstream signal
components.
Consistent with these results, p-CRAF, CRAF, and p-ERK
were reduced in shRNA transfected mKRAS cells upon Dox
treatment as well as in fibroblasts from GSTP-gene-deleted
Gstp1p2−/− mice (Fig. 3 B and C). These observations were further
supported by results showing that transduction of GSTP1 to
WTKRAS cells brought about enhanced expression of p-CRAF
(Ser338), CRAF, p-MEK1/2 (Ser217/Ser221), and p-ERK1/2
(Thr202/Tyr204) (Fig. 3D).
Direct Binding of GSTP1 at the Regulatory Domain of CRAF, Promotes
the Growth of mKRAS KRAS Cells. The possibility that GSTP1 in-
teracts with CRAF and prevents its degradation was explored. As
revealed by immunoprecipitation/immunoblotting methods,
GSTP1 was coprecipitated with both p-CRAF (Ser338) and
CRAF in all three cell lines examined whereas coprecipitation of
GSTP1 with BRAF was not detected (Fig. 4A).
To directly substantiate the GSTP1/CRAF interaction, biol-
ayer interferometry analysis (BLItz assays) using recombinant
CRAF, BRAF, and GSTP1 was performed. Binding of GSTP1 to
CRAF (Fig. 4 B, Upper) with relatively high affinity (Fig. 4B
lower histogram) was noted, yet no binding to BRAF was de-
tected. This assay also showed that S alkylation of Cys residues of
CRAF did not affect the binding to GSTP1 (Fig. 4B), suggesting
no direct involvement of cysteine residues or disulfide bridges in
the interaction.
As a plausible explanation for the observation that, despite the
conserved amino acid sequences of CRAF and BRAF, both
known to play an essential role forming dimers in mKRAS sig-
naling, GSTP1 binds only to CRAF. The presence of a flexible
Gly-, Ala-Ser rich N-terminal extension of BRAF not in CRAF
was presumed to sterically interfere with the binding of GSTP1
to BRAF, whereas CRAF, which lacks this extension can ac-
commodate GSTP1. This postulate was confirmed by pull-down
assays which demonstrated that an N-terminal deletion mutant
of BRAF accommodated GSTP1 in a manner comparable to
that of intact CRAF (Fig. 4C). The finding that the regulatory
domain, CR1-deleted mutant of CRAF no longer bound to
GSTP1, suggests that the binding region for GSTP1 is in the CR1
region (Fig. 4C).
Stabilization, Dimerization, and Activation of CRAF by GSTP1 in
mKRAS Cells. To explore potential mechanisms by which binding
of GSTP1 enhances CRAF levels, effects on CRAF turnover and
its ubiquitination status in mKRAS cells were examined by im-
munoblotting. CRAF ubiquitination was, indeed, increased after
siGSTP1 treatment of the cells (Fig. 5A). Moreover, treatment of
the cells with a proteasome inhibitor MG132 brought about
restoration of reduced p-CRAF (Ser338) and CRAF (Fig. 5B),
indicating that, by binding of GSTP1, ubiquitination and pro-
teasomal degradation of CRAF is impeded.
Since RAF dimers are considered to be the active forms to
transduce the signal (21), efforts were then made to determine
whether GSTP1 participates in dimer formation of CRAFs
which were visualized by double transfection of FLAG-tagged
and V5-tagged CRAF followed by immunoprecipitation with
anti-FLAG antibodies and, subsequently, immunoblotting with
anti-V5 antibodies. When these cells were treated with siGSTP1,
the intensity of the V5-CRAF band was significantly reduced as
compared to that of the FLAG-CRAF band (Fig. 5 C, Upper and
lower histogram), indicating that the effect of siGSTP1 to reduce
dimerized V5-CRAF to FLAG-CRAF was more marked than
that to reduce FLAG-CRAF itself by destabilization. To cor-
roborate the GSTP1-dependent dimerization, bimolecular lu-
minescence complementation (BiLC) assays were additionally
performed. The luminescence intensity of CRAF-FLAG-LgBit/
SmBit-CRAF-FLAG was dramatically suppressed to below 20%
of its value by siGSTP1 (SI Appendix, Fig. S6A) whereas ex-
pression of each protein revealed by Western blotting was re-
duced to only 60% after siGSTP1 treatment (SI Appendix, Fig.
S6B). Furthermore, introduction of the GSTP1 plasmid into
WTKRAS cells clearly augmented CRAF dimer formation as
indicated by more increased V5-CRAF than FLAG-CRAF
(Fig. 5D), confirming the role of GSTP1 in CRAF dimer
formation.
Since CRAF/BRAF heterodimers have been shown to be ac-
tive in mKRAS cells (22), the effect of siGSTP1 on this hetero-
dimer formation was also analyzed. Silencing of GSTP1 in the
mKRAS cells, which were doubly transfected with V5-CRAF and
FLAG-BRAF resulted in significantly more reduction of FLAG-
BRAF than V5-CRAF (Fig. 5E). These results suggest that
binding of GSTP to CRAF is sufficient to induce its hetero-
dimerization with BRAF which is without bound GSTP1.
To determine whether the catalytic activity of FLAG-CRAF
immunity precipitated from WTKRAS cells, transfected with
FLAG-CRAF, is enhanced by addition of GSTP1, in vitro kinase
assays targeting MEK1 were performed. The results explicitly
confirmed that phosphorylation of MEK1 by FLAG-CRAF was,
indeed, enhanced in the presence of GSTP1 relative to that in its
absence (Fig. 5F). When a similar experiment was performed
with FLAG-CRAF and FLAG-BRAF immunities precipitated
from the WTKRAS cells, augmentation of MEK1 phosphoryla-
tion by GSTP1 was also confirmed (Fig. 5G).
Furthermore, to elucidate the role of GSTP1 activity in sta-
bilization against proteasomal degradation versus dimerization
of CRAF, we examined the effect of forced expression of
degradation-resistant mutant CRAF on growth suppression by
siGSTP1 in mKRAS PANC-1 cells. GSTP1 played an almost
equal role in protection against proteasomal degradation and in
facilitation of dimerization (SI Appendix, Fig. S7).
Autocrine Loop of CRAF/MEK/ERK Generated by GSTP1 in Both mKRAS
and mBRAF Cells. The findings described above prompted us to
postulate that the function of GSTP1 in signaling pathways of
mKRAS cells is the facilitation of the CRAF/MEK/ERK cascade
in an autocrine loop, paralleling the stimuli of mKRAS. This
postulate was verified by an experiment applying combinations
of siRNAs KRAS (siKRAS) and siGSTP1. Four different siR-
NAs against KRAS were equally effective in silencing the KRAS
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Fig. 3. Attenuation of CRAF/MEK/ERK signaling by GSTP1 silencing in mKRAS cancer cells and by forced expression of GSTP1 in wtKRAS cancer cells. (A)
Decreased phosphorylation of CRAF/MEK/ERK and CRAF protein in siGSTP1 treated mKRAS in the indicated cancer cells. Cells were transfected with siGSTP1
then lysed at day 3. Lysates were analyzed by immunoblotting for each signal component using corresponding antibodies. (B) Suppressed p-CRAF, CRAF, and
p-ERK in shGSTP1 transfected mKRAS cells treated with Dox. GFP expressing cloned M7609 and A549 cells (refer to Materials and Methods for details) were
treated with Dox and lysed at day 2. The lysate underwent immunoblotting for GSTP1, p-CRAF, CRAF, p-ERK, and β-actin with each corresponding antibody.
(C) Impaired CRAF/MEK/ERK signaling in skin fibroblasts from Gstp1p2 null mice. Lysates of skin fibroblasts from Gstp1p2 null mice were analyzed by im-
munoblotting for each signal component using corresponding antibodies. (D) Enhancement of CRAF/MEK/ERK signaling in wtKRAS cancer cells by forced
expression of GSTP1. HeLa cells were infected with 10 MOI of AxCAhGSTP1, recombinant adenovirus expressing GSTP1 and AxCAwt, control adenovirus for 1
h, and lysed at day 2 of the infection. Lysates were analyzed by immunoblotting for each signal component using corresponding antibodies. Densitometry
analysis indicates relative protein levels from one representative of three independent experiments.
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Fig. 4. Binding of GSTP1 to CRAF at its N-terminal domain in mKRAS cells. (A) Coimmunoprecipitation of GSTP1 with p-CRAF (Ser338) and CRAF but not with
BRAF in KRAS mutant cancer cells. GSTP1 in lysates of mKRAS cells was coimmunoprecipitated with p-CRAF (Ser338) and CRAF antibodies and subjected to its
immunoblotting. Normal immunoglobulin G (IgG) was used as a negative control for immunoprecipitation. Coimmunoprecipitation of GSTP1 with BRAF was
carried out with two different anti-BRAF antibodies, lanes 1 and 2, in M7609 cells. (B) Kinetic analysis of the interaction between GSTP1 and CRAF and BRAF
and alkylated CRAF by biolaser interferometry. Experiments for GSTP1 binding to each target protein were triplicated as shown in upper graphic figures.
Dissociation constants for each binding based on the curves in Upper are shown in the lower histogram panel. (C) Coimmunoprecipitation of GSTP1 with
FLAG-CRAF, FLAG-BRAF, FLAG-CRAF deleted of N-terminal CR1 motif (CRAFΔN), and FLAG-BRAF deleted of BRSR motif (BRAFΔN) from the lysate of mKRAS
cells transfected with each corresponding plasmid. The schematic construct of each plasmid is shown in Upper. GSTP1 was pulled down with anti-FLAG
antibodies from the lysate of mKRAS cancer cells which were transfected with each expression plasmid, cultured for 48 h, and subjected to Western blotting.
Lower represents results of Western blotting. CR1, conserved regions 1; BRSR and BRAF specific N-terminal region.






















































































































































































































































































































































































Fig. 5. Increased proteasomal degradation and decreased dimer formation of CRAF in siGSTP1 treated mKRAS cancer cells, and enhancement of kinase
activity of CRAF by addition of GSTP1 in vitro. (A) Increased ubiquitination of CRAF by siGSTP1 silencing in mKRAS cancer cells. Ubiquitination of CRAF was
evidenced by Western blotting using anti-ubiquitin antibodies. Equal loading of immunoprecipitates was confirmed by immunoblotting of the IgG heavy
chain. (B) Recovery of CRAF by MG132 in siGSTP1 treated mKRAS cancer cells. After siGSTP1 transfection, cells were treated with 5 μM of MG132 for 4 h and
lysed. Lysates were analyzed by immunoblotting for p-CRAF and CRAF. (C) Decreased CRAF homodimers in siGSTP1-treated mKRAS cancer cells. After
transfection of siGSTP1 or siControl, cells were cotransfected with FLAG-CRAF and V5-CRAF, cultured for 48 h, and lysed. Lysates were immunoprecipitated
with the FLAG antibody and subjected to immunoblotting with the V5 antibody. Difference in band intensity for V5-CRAF and FLAG-CRAF in siGSTP1-treated
cells was calculated on the data of three independent experiments and was expressed in a histogram after normalizing their intensities to those in siControl
treated cells. *P < 0.01 by repeated one-way ANOVA. (D) Increased CRAF homodimer in GSTP1 transduced WTKRAS cancer cells. After cotransfection with
FLAG-tagged CRAF and V5-tagged CRAF, MCF7 cells were cultured for 24 h, transfected with FLAG-GSTP1 or control vector, and lysed. Lysates were
immunoprecipitated with the FLAG antibody and subjected to immunoblotting using corresponding antibodies. Difference in band intensity for V5-CRAF and
FLAG-CRAF was statistically analyzed as described in C. *P < 0.01 by repeated one-way ANOVA. (E) Decreased CRAF/BRAF heterodimer in siGSTP1 transfected
mKRAS cancer cells. After siGSTP1 transfection, M7609 cells were cotransfected with V5-tagged CRAF and FLAG-tagged BRAF and lysed. Lysates were
immunoprecipitated with the V5 antibody and subjected to immunoblotting with the V5-CRAF and FLAG antibodies. Statistical analysis for the difference in
band intensity of V5-CRAF and FLAG-BRAF was carried out similarly as C and D. *P < 0.01 by repeated one-way ANOVA. (F) Activation of CRAF kinase activity
by GSTP1. HeLa cells were transfected with FLAG-CRAF, and 48 h later, FLAG-CRAF proteins immunopurified were incubated with GSTP1 in kinase reaction
mixture containing inactive MEK1, ATP, and Mg2+. Kinase activity of CRAF was analyzed by immunoblotting of p-MEK1 (Ser217). Relative intensities of
GSTP1(+) bands to those of GSTP1(−) in three independent experiments were expressed in the right histogram. *P < 0.01 by repeated one-way ANOVA. (G)
Activation of CRAF/BRAF kinase activity by GSTP1. FLAG-CRAF and FLAG-BRAF proteins immunopurified from HeLa cells were incubated with GSTP1 in kinase
reaction mixture, and kinase activity was analyzed by immunoblotting of p-MEK1 (Ser217). Relative intensities of GSTP1(+) bands to those of GSTP1(−) in
three independent experiments were expressed in the right histogram. *P < 0.01 by repeated one-way ANOVA.








































gene in mKRAS cells, most likely ruling out off-target effects (SI
Appendix, Fig. S8A). Dose-dependent suppression of cell growth
was confirmed with siKRAS-A (SI Appendix, Fig. S8B). When
siKRAS and siGSTP1 were cotransfected in these cells, additive
growth suppression was observed as compared to that found with
each individual siRNA (Fig. 6A). These data establish that, once
GSTP1 is induced, growth signals may be enabled through this
cascade independently of the upstream stimulus of mKRAS
(scheme, Fig. 6B). Comparable functions of GSTP1 were dis-
played in mBRAF cells. In those cells, silencing of GSTP1, which
apparently has no direct interaction with mBRAF, also caused
significant growth suppression (SI Appendix, Fig. S8C) with im-
paired CRAF/MEK/ERK signaling (SI Appendix, Fig. S8D)
by itself.
Moreover, in a manner similar to the case of mKRAS cells, in
the mBRAF cells which showed dose-dependent sensitivity to its
inhibitor PLX4720 (SI Appendix, Fig. S8E), additive growth
suppression effects of siGSTP1 were observed when mBRAF
cells were treated with siGSTP1 in combination with PLX4720
(Fig. 6C). The growth promoting effects of CRAF/GSTP1 inter-
actions in mBRAF cells, although not as great as those in mKRAS
cells, were substantiated by growth suppression observed using
siCRAF (SI Appendix, Fig. S9 A and B). Thus, in mBRAF cells, the
autocrine loop of GSTP1 also functions (scheme, Fig. 6D).
Discussion
The results reported here are consistent with the view that, in
mKRAS cancers, there is a direct cause-and-effect relationship
between mKRAS and GSTP1 expression and that the GSTP1-
CRAF interaction perpetuates an autocrine cycle that circum-
vents the primary growth signal. The fundamental concept is
outlined in the scheme (Fig. 6B).
Underlying the mechanism for the autocrine growth promo-
tion, there are three indispensable molecular events disclosed in
this study: enrichment of CRAF through inhibition of protea-
somal degradation, CRAF stabilization effects of GSTP1 facili-
tation of the RAF dimer (CRAF-CRAF and CRAF-BRAF)
formation, and activation of catalytic activity of CRAF. It has
been proposed that the N-terminal receptor binding domain
(RBD) lobe of CRAF folds over and obstructs the C-terminal
catalytic lobe (21). We suggest that activation as well as en-
hanced dimerization of CRAF occur upon GSTP1 binding to the
RBD reported here which prevents this folding and opens di-
merization capacity with other RAF family members (23). It is
reasonable to propose a similar mechanism as that for dimer-
ization can take place for activation of CRAF by GSTP1 to
transduce the signal to the downstream protein MEK. The
suggestion that GSTP1 involves both dimer formation and acti-
vation of CRAF is consistent with previous reports, indicating
that dimerization is a critical step for activation of RAF enzyme
activity (21). In this regard, elucidation of the possibility that S-S
glutathionylation of cRaf is relevant to the dimerization of ac-
tivation mechanisms is a future task.
A unique and intriguing characteristic of the proposed auto-
crine cycle is that, once GSTP1 is expressed, it keeps functioning
bypassing mutations of KRAS. This notion was substantiated by
the findings that siGSTP1 exerted additive effects to the inhibi-
tion of mKRAS. Involvement of GSTP1 in the autocrine growth
cycle of mKRAS cells was verified by effects of gene silencing on
both in vitro cell proliferation and tumorigenesis of xenografted
cells as well as effects of gene transfection on cell proliferation
and of gene deletion on colon carcinogenesis.
With regard to the GSTP1 silencing effects on tumorigenesis,
results seemingly consistent with our observations have previ-
ously been reported (16, 24, 25). However, those studies neither
explored molecular mechanisms of GSTP1 functions in cancer
growth nor considered GSTP1 involvement in autocrine signal-
ing. Furthermore, the growth promoting activity of GSTP1 was
simply ascribed to inhibition of JNK (16, 24, 25). Moreover, the
present study established that inhibition of JNK is unlikely to be
a mechanism of growth promotion by GSTP1.
With regard to the colon carcinogenesis in Gstp1p2 null mice,
there is an apparent contradiction between our results and those
of previous reports. Contrary to the impaired carcinogenesis in
the present study, enhanced skin and lung cancers in Gstp1p2
null mice were reported (26, 27). However, in those previous
studies, as the authors pointed out, the carcinogens were sur-
mised to be detoxified by Gstp1p2 in WT mice and, thus, less
active to induce cancers as compared to those in GSTp1p2 null
mice, resulting in relatively increased carcinogenesis in the latter
mice. In this regard, it may be reasonable to conclude that, un-
like carcinogens in previous reports, our carcinogen AOM used
in the present study is not detoxified by GSTp1p2 because
treatment with AOM, indeed, induced ACF and colon cancers
even in the presence of GSTp1p2 in WT mice, and AOM rather
needed GSTp1p2 for its activity to induce mKRAS cancers since,
in GSTp1p2 null mice, formation of these lesions was signifi-
cantly impaired. Since, in mBRAF cancers, the MEK/ERK cas-
cade which should induce expression of GSTP1 is the primary
growth signal, and in the current investigation, GSTP1 was, indeed,
expressed in all mBRAF cells examined, it is highly likely that the
autocrine growth cycle is active in these cancers as well even though
BRAF itself does not accommodate GSTP1 binding. Consistent
with this assumption, siGSTP1 was effective to suppress the growth
of mBRAF cells alone and showed additive growth suppression in
combination with BRAF inhibitors. Thus, as shown in the scheme
in Fig. 6D, the bypass of BRAF mutations by linkage of GSTP1 to
the CRAF’s proliferation promoting function is considered to be,
indeed, active in mBRAF cells as well.
In a series of previous studies, the strategy of utilizing small
molecule inhibitors of GSTP1 enzymatic activity to impede
cancer cell growth has been widely sought (28–30). However,
those approaches may not necessarily be effective to suppress the
GSTP1-CRAF interaction cited here. Recently, Louie et al.
showed that silencing and/or inhibition of GSTP1 selectively
blocked growth of triple-negative breast cancers (31). This in-
hibitory effect was attributed to interference with proposed
GSTP1 activation of GAPDH that enhances glycolysis in the
cancer cells, but the role of GSTP1 in growth promotion via
CRAF/MEK/ERK signaling was not considered. In addition,
targeting GSTP1 using GSTP1 inhibitors or siGSTP1 described
in this study and in some previous reports may engender unde-
sirable adverse effects since GSTP1 is known to interact with
several intracellular factors and various biological functions (32,
33). Therefore, strategies to specifically block CRAF/GSTP1
interactions may be more desirable. In this regard, results
showing that GSTP1 also bound S-alkylated CRAF (Fig. 4B)
indicate that the CRAF-GSTP1 binding is likely to be non-
covalent and need not involve disulfide bridges or S gluta-
thionylation (33, 34), suggesting potential strategies blocking the
CRAF/GSTP1 interactions.
In conclusion, the essential growth signaling CRAF/MER/
ERK cascade in cancers, such as those with mKRAS and mBRAF
cells, can be controlled by specific interactions of CRAF with
GSTP1 in the promotion of an autocrine growth cycle. Accord-
ingly, prospects for innovative therapeutic approaches to have
eventual translational relevance to these cancers may be devel-
oped based on the strategy to interfere with the CRAF-GSTP1
interaction.
Materials and Methods
Biolayer Interferometry. Dissociation constants (Kd) between GSTP1 and RAFs
(CRAF and BRAF) were determined using the BLItz system (ForteBio)
according to the manufacturer’s instructions. Biosensor chips with carboxyl
groups (amine reactive second-generation biosensor [ForteBio]) were hydrated
overnight prior to the experiment in water. Placental GSTP1 (Sigma-Aldrich)

















































































































































































































































































































BRAF (V600E) mutant cellD
Fig. 6. Additive effects of siGSTP1 on the growth of siKRAS-treated mKRAS cancer cells and BRAF inhibitor-treated mBRAF cells. (A) Additive suppressive
effects of siGSTP1 on the growth of siKRAS-treated mKRAS cancer cells. At day 2 of 50 nM siGSTP1 transfection, M7609 cells were treated with siKRAS at 10
nM, and cell numbers were counted at day 5. Data represent the mean ± SD of three independent experiments. *P < 0.01 by repeated one-way ANOVA. (B)
Schematic of proposed autocrine activation of CRAF by GSTP1 in mKRAS cells. Note that, in mKRAS cells, the growth signal from mKRAS is augmented by
GSTP1, end product of the signal, through interaction with CRAF. (C) Additive suppressive effects of siGSTP1 on the growth of inhibitor-treated mBRAF cancer
cells. mBRAF cancer cells were transfected with 50 nM siGSTP1 or siControl, and at day 2 additionally treated with PLX4720 at each indicated concentration.
At day 5, cell numbers were counted. Data represent the mean ± SD of three independent experiments. *< 0.05; **P < 0.01 by repeated one-way ANOVA. (D)
Schematic of autocrine activation of CRAF by GSTP1 in mBRAF cells. Note that in mBRAF cells, the autocrine feedback loop is overriding the primary
mBRAF signal.








































was immobilized on the biosensor in acetate buffer (pH 3.0). After immobili-
zation, the redundant carboxyl groups were blocked by ethanolamine (Wako
chemicals). Recombinant CRAF (Origene) and BRAF (Origene) were used with-
out dilution in the association step. The buffer (25 mM Tris·HCl, pH 7.3, 100 mM
glycine, 10% glycerol) was used for equilibration and dissociation steps, which
is same composition as supplied by recombinant CRAF and BRAF solutions. The
time course of BLItz experiments for obtaining baseline, immobilization,
blocking, equilibration, association, and dissociation were 300, 300, 120, 30,
120, and 120 s, respectively. All assays were performed in triplicate.
In Vitro Kinase Assays. HeLa cells were transfected pcDNA3.1-FLAG-CRAF and
pCMV6-Myc-DDK-BRAF (Addgene) using FuGENE6 HD, treated with 50 ng/mL
epidermal growth factor (BD Biosciences) for 10 min and lysed with 0.5%
Nonidet P-40 lysis buffer on ice for 30 min after 48 h. Protein lysates were
clarified by centrifugation at 13,000 × g for 10 min at 4 °C, incubated with
anti-FLAG M2 affinity gel (Sigma-Aldrich) for 2 h at 4 °C, and washed with
0.5% Nonidet P-40 lysis buffer four times. To stabilize GSTP1 with GSH, 1 μg
of human placental GSTP1 (Sigma-Aldrich) was preincubated with 2–5 mM
glutathione in 0.1 M phosphate buffer, pH 6.5 for 20 min at 37 °C. After
washing with assay dilution buffer I (Merck-Millipore), FLAG-CRAF protein
and/or FLAG-BRAF was incubated with 1 μg of placental GSTP1 and 1 μg of
inactive MEK1, magnesium/ATP mixture (Merck-Millipore) in assay dilution
buffer I (Merck-Millipore) for 1 h at 30 °C. Kinase activity was analyzed by
immunoblotting for p-MEK1 (Ser217).
Animals. All experiments were undertaken in accordance with criteria out-
lined in a license granted under the Animals (Scientific Procedures) Act 1986
and approved by the Animal Ethics Committees of the Sapporo Medical
University.
More detailed information about theMaterials and Methods of this study
are provided in the SI Appendix.
Data Availability. All data relevant to this paper are available in the main text
and SI Appendix.
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